TLSA icon

Tiziana Life Sciences

1.31 USD
-0.05
3.68%
At close Apr 28, 4:00 PM EDT
After hours
1.31
+0.00
0.00%
1 day
-3.68%
5 days
15.93%
1 month
16.96%
3 months
84.48%
6 months
32.32%
Year to date
92.42%
1 year
103.04%
5 years
-55.29%
10 years
-84.31%
 

About: Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Employees: 9

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 9

10% more funds holding

Funds holding: 30 [Q3] → 33 (+3) [Q4]

0.98% less ownership

Funds ownership: 1.88% [Q3] → 0.91% (-0.98%) [Q4]

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

61% less capital invested

Capital invested by funds: $1.78M [Q3] → $698K (-$1.08M) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for TLSA.

Financial journalist opinion

Based on 4 articles about TLSA published over the past 30 days

Positive
Proactive Investors
5 days ago
Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of Massachusetts
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the University of Massachusetts has commenced dosing patients in its ongoing Phase 2 trial of its lead candidate intranasal foralumab, a fully human anti CD3 monoclonal antibody, for non-active secondary progressive multiple sclerosis (na-SPMS). UMass joins Brigham and Women's Hospital, Yale Multiple Sclerosis Center, and Johns Hopkins University in actively enrolling and treating trial participants.
Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of Massachusetts
Neutral
GlobeNewsWire
5 days ago
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS).
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
Positive
Proactive Investors
3 weeks ago
Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that Johns Hopkins University has begun dosing patients in its Phase 2 clinical trial evaluating intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This marks the third clinical site for the trial, alongside Brigham and Women's Hospital and Yale Medical Center.
Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins
Neutral
GlobeNewsWire
3 weeks ago
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced dosing has commenced at Johns Hopkins University (JHU) Autoimmunity Center of Excellence, the third clinical site in its Phase 2 trial evaluating intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
Positive
Proactive Investors
1 month ago
Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it has begun dosing patients at Yale MS Center in its multicenter Phase 2 trial evaluating intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for non-active secondary progressive multiple sclerosis (na-SPMS). The study, which aims to assess the safety and effectiveness of foralumab in mitigating disease progression, is also enrolling patients at Johns Hopkins, UMass Medical Center, and Brigham and Women's Hospital, the company said in a statement.
Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS
Neutral
GlobeNewsWire
1 month ago
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced dosing of new patients at Yale MS Center which is participating in our multicenter Phase 2 clinical trial evaluating intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
Neutral
GlobeNewsWire
1 month ago
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the CEO of Tiziana Life Sciences, Ivor Elrifi, will be presenting during a fireside chat at the 37th Annual ROTH Conference and host 1x1 investor meetings. The Conference is being held March 16-18, 2025, in Dana Point, California. This year's event will consist of 1-on-1 / small group meetings, analyst-selected fireside chats, industry keynotes and panels with executive management attending from approximately 450 private and public companies in a variety of growth sectors.
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
Neutral
GlobeNewsWire
1 month ago
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq Capital Market exchange.
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
Positive
Proactive Investors
1 month ago
Tiziana submits FDA investigational new drug application
Tiziana Life Sciences Ltd has filed an investigational new drug application with the Food and Drug Administration for a clinical trial in Amyotrophic Lateral Sclerosis (ALS). Tiziana, which is advancing lead candidate intranasal foralumab, said on Tuesday it planned a phase two trial including 20 patients upon clearance.
Tiziana submits FDA investigational new drug application
Neutral
GlobeNewsWire
1 month ago
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial in ALS.
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
Charts implemented using Lightweight Charts™